Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

 Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively

Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments

Read more at globenewswire.com